{"organizations": [], "uuid": "0291e94f008d2db3dcbe398df035019790212966", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 72, "shares": 72, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://images.wsj.net/im-5705/social", "site_section": "http://online.wsj.com/xml/rss/3_8068.xml", "section_title": "WSJ.com US News", "url": "https://www.wsj.com/articles/drug-price-hike-sparks-senate-probe-1522677600", "country": "US", "domain_rank": 387, "title": "Drug Price Hike Sparks Senate Probe", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-02T18:00:00.000+03:00", "replies_count": 0, "uuid": "0291e94f008d2db3dcbe398df035019790212966"}, "author": "Peter Loftus", "url": "https://www.wsj.com/articles/drug-price-hike-sparks-senate-probe-1522677600", "ord_in_thread": 0, "title": "Drug Price Hike Sparks Senate Probe", "locations": [], "entities": {"persons": [{"name": "claire mccaskill", "sentiment": "none"}, {"name": "susan collins", "sentiment": "none"}, {"name": "robert dicrisci", "sentiment": "none"}, {"name": "dicrisci", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "florida", "sentiment": "none"}, {"name": "maine", "sentiment": "none"}, {"name": "mo.", "sentiment": "none"}], "organizations": [{"name": "tri-source pharma llc", "sentiment": "none"}, {"name": "nextsource biotechnology", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Three U.S. senators are seeking more information from a Florida company that has steadily increased the price of a 40-year-old cancer drug, lomustine, in recent years.\n\nSens. Susan Collins (R., Maine), Claire McCaskill (D., Mo.) and Catherine Cortez Masto (D., Nev.) sent a letter dated March 22 to Tri-Source Pharma LLC Chief Executive Robert DiCrisci, saying, “We would like to better understand the factors contributing to the rising cost of lomustine.” Mr. DiCrisci also is CEO of NextSource Biotechnology, the Tri-Source unit... To Read the Full Story Subscribe Sign In", "external_links": [], "published": "2018-04-02T18:00:00.000+03:00", "crawled": "2018-04-02T18:46:45.015+03:00", "highlightTitle": ""}